Efficacy and Safety of Treatment With Deuruxolitinib in Adults With Alopecia Areata
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
J Am Acad Dermatol 2024 Jul 23;[EPub Ahead of Print], B King, MM Senna, NA Mesinkovska, C Lynde, M Zirwas, C Maari, VH Prajapati, S Sapra, P Brzewski, L Osman, S Hanna, MC Wiseman, C Hamilton, J CassellaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.